MSLN and acute myeloid leukemia: Several surface markers have been proposed as targets for AML because of their relative abundant expression on leukemic cells, including CD123 (IL3Rα), CD44, CD47, CD70, CD96, mesothelin, and CLECL12A/CLL-178–84.